News

St. Renatus announces favorable FDA review

Monday, March 07, 2011

St. Renatus, LLC (Fort Collins) announced that the company had a favorable End of Phase 2 review with the U.S. Food and Drug Administration (FDA), and agreed that in the near future, the company will proceed with conducting Phase 3 efficacy studies to determine the exact parameters for their nasal mist dental anesthetic achieving dental anesthesia in the maxillary arch.  St. Renatus and the FDA discussed details for both Phase 3 Adult and Pediatric studies to be conducted in the near future. Final revised protocols will be forwarded to the FDA in the coming weeks.  

CaridianBCT to be sold for $2.6B

Monday, March 07, 2011

(Reuters) - Terumo Corp (4543.T) said it would buy U.S. medical device company CaridianBCT from a Swedish firm for about $2.6 billion, marking the largest acquisition by a Japanese medical equipment maker. 

N30 Pharmaceuticals to Present Preclinical Data

Thursday, March 03, 2011

N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting. 

Bioscience industry teams with CSU

Wednesday, March 02, 2011

Bioscience Industry Teams with Colorado State University to Create Online Regulatory and Clinical Trial Management Certificate Programs 

VetDC acquires rights from Gilead

Wednesday, March 02, 2011

FT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., today announced that the company has acquired from Gilead Sciences, Inc. an exclusive North American license to develop and commercialize Gilead's investigational molecule, GS 9219, for use in animal cancer. GS 9219 is an anti-proliferative agent that preferentially targets lymphoid cells and works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.  

Arcturus Star Products works with Australian researchers to help women with lymphedema

Tuesday, March 01, 2011

 

Omni Bio Pharmaceutical expands human clinical trial

Monday, February 28, 2011

Omni Bio Pharmaceutical, Inc. (Greenwood Village) has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50.The expansion of the trial population has been approved by the FDA.  The trial, which is currently underway at the Barbara Davis Center for Childhood Diabetes at the University of Colorado-Denver Anschutz Medical Campus, has seen improvement in the condition of the first enrolled patients. The expansion of the clinical trial would result in an increase of clinical trial service costs of approximately $2 million, excluding drug costs, and would require Omni Bio to raise additional financing before the expansion of the trial can begin.   

MDMA Washington Update - Feb 25

Monday, February 28, 2011

House Hearing Scrutinizes FDA's Impact on Job Creation and Innovation  

BioAMPS International receives Phase 2 contract

Monday, February 28, 2011
BioAMPS International receives Phase 2 contract from Office of Naval Research to develop new antibiotic class for treatment of drug resistant gram-negative bacteria 
Continue Reading

Ariel founder takes new approach for startup capital

Friday, February 25, 2011